Cytokines and vascular reactivity in resistance arteries

被引:149
作者
Vila, E [1 ]
Salaices, M
机构
[1] Univ Autonoma Barcelona, Fac Med, Inst Neurociences, Dept Farmacol Terapeut & Toxicol, Bellaterra 08193, Spain
[2] Univ Autonoma Madrid, Fac Med, Dept Farmacol, Madrid, Spain
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2005年 / 288卷 / 03期
关键词
inflammation; cardiovascular diseases;
D O I
10.1152/ajpheart.00779.2004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 288: H1016 - H1021, 2005; doi: 10.1152/ ajpheart. 00779.2004. - Cytokine levels are elevated in many cardiovascular diseases and seem to be implicated in the associated disturbances in vascular reactivity reported in these diseases. Arterial blood pressure is maintained within a normal range by changes in peripheral resistance and cardiac output. Peripheral resistance is mainly determined by small resistance arteries and arterioles. This review focuses on the effects of cytokines, mainly TNF-alpha, IL- 1beta, and IL- 6, on the reactivity of resistance arteries. The vascular effects of cytokines depend on the balance between the vasoactive mediators released under their influence in the different vascular beds. Cytokines may induce a vasodilatation and hyporesponsiveness to vasoconstrictors that may be relevant to the pathogenesis of septic shock. Cytokines may also induce vasoconstriction or increase the response to vasoconstrictor agents and impair endothelium dependent vasodilatation. These effects may help predispose to vessel spasm, thrombosis, and atherogenesis and reinforce the link between inflammation and vascular disease.
引用
收藏
页码:H1016 / H1021
页数:6
相关论文
共 52 条
[1]  
Bernard C, 1992, Eur Cytokine Netw, V3, P19
[2]  
Bilsborough W, 2002, CLIN SCI, V103, P163
[3]   Inflammatory bio-markers and cardiovascular risk prediction [J].
Blake, GJ ;
Ridker, PM .
JOURNAL OF INTERNAL MEDICINE, 2002, 252 (04) :283-294
[4]   Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure [J].
Bozkurt, B ;
Torre-Amione, G ;
Warren, MS ;
Whitmore, J ;
Soran, OZ ;
Feldman, AM ;
Mann, DL .
CIRCULATION, 2001, 103 (08) :1044-1047
[5]   Tumor necrosis factor-α-induced dilatation of cerebral arterioles [J].
Brian, JE ;
Faraci, FM .
STROKE, 1998, 29 (02) :509-515
[6]  
BRIONES AM, 2004, J VASC RES, V41, pA2
[7]   NEGATIVE FEEDBACK-REGULATION OF ENDOTHELIAL-CELL FUNCTION BY NITRIC-OXIDE [J].
BUGA, GM ;
GRISCAVAGE, JM ;
ROGERS, NE ;
IGNARRO, LJ .
CIRCULATION RESEARCH, 1993, 73 (05) :808-812
[8]   Location of resistance arteries [J].
Christensen, KL ;
Mulvany, MJ .
JOURNAL OF VASCULAR RESEARCH, 2001, 38 (01) :1-12
[9]   Mechanisms of diabetic vasculopathy: An overview [J].
Cooper, ME ;
Bonnet, F ;
Oldfield, M ;
Jandeleit-Dahm, K .
AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (05) :475-486
[10]  
CORDER R, 1995, J CARDIOVASC PHARM, V26, pS56